BioSpace News Archive

Extendicare Inc. (“Extendicare” or the “Company”) (TSX: EXE) announced that it has declared a cash dividend of C$0.04 per common share of the Company (the “Common Share”) for the month of February 2022, which is payable on March 15, 2022 to shareholders of record at the close of business on February 28, 2022.

BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on the development and commercialization of 2nd generation non-hallucinogenic psychedelic analogs...

Monopar Therapeutics Inc. today announced program updates across its pipeline and anticipated 2022 highlights.

Inari Medical, Inc. (NASDAQ: NARI) (“Inari”) today announced that the first patient has been enrolled in PEERLESS, a prospective, randomized controlled trial (“RCT”) comparing the outcomes of patients with intermediate-high risk pulmonary embolism (“PE”) treated with the FlowTriever system versus catheter-directed thrombolysis (“CDT”).

Centene Corporation (NYSE: CNC) today announced that the National Committee for Quality Assurance (NCQA) has awarded Trillium Community Health Plan a Health Plan Accreditation status of “Accredited” for the Medicaid product.

Velocity Clinical Research (“Velocity”), the largest fully integrated clinical site organization, today announces three key tech investments to expand its patient community, increase client engagement, and speed up drug development across all its 30 integrated locations.

ImpediMed Limited (ASX.IPD), is pleased to announce an abstract comparing concurrent measures using ImpediMed’s SOZO® Digital Health Platform and dual x-ray absorptiometry (DXA) for assessing bone mineral content in cancer patients was accepted for poster presentation at the 39th Annual Miami Breast Cancer Conference.

CloudCath Inc., a private medical device company advancing real-time fluid analytics and remote monitoring of infectious diseases, announced today it received U.S. Food and Drug Administration (FDA) clearance for the CloudCath System, the world’s first data-driven, cloud-based, remote monitoring platform for PD patients in the $74.5B end-stage renal disease (ESRD) market.

Element Biosciences, developer of a new and disruptive DNA sequencing platform, today announced the appointment of Shawn Levy, PhD, as Senior Vice President of Applications and Scientific Affairs.

Kallyope, Inc., a leading biotechnology company focused on identifying and developing therapeutics involving the gut-brain axis, today announced the closing of a $236 million Series D financing co-led by Mubadala Investment Company and The Column Group, along with participation from other new and existing investors.